| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/24/2005 | US20050065124 Method for treating benign prostatic hyperplasia |
| 03/24/2005 | US20050065123 Administering to a post menopausal woman an effective amount of 2-methylene -19-nor-20(S)-1 alpha ,25-dihydroxyvitamin D3 |
| 03/24/2005 | US20050065122 Taurine compounds |
| 03/24/2005 | US20050065121 Using probucol ester |
| 03/24/2005 | US20050065120 Compositions and methods for the treatment of urinary incontinence |
| 03/24/2005 | US20050065118 Compound containing 1,3,4-thiadiazole group; anticancer agents; autoimmune disease; antidiabetic agents |
| 03/24/2005 | US20050065117 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate |
| 03/24/2005 | US20050065116 Thiazolopyrimidines useful as TNFalpha inhibitors |
| 03/24/2005 | US20050065115 N,N-dihalogenated amino acids and derivatives |
| 03/24/2005 | US20050065114 Antitumor, anticancer agents; viricides; bactericides; fungicides; immunology stimulants |
| 03/24/2005 | US20050065112 Antiproliferative agents; low toxicity; psoriasis; antitumor agents; rheumatic arthritis; gastrointestinal disorders; antiinflamamtory agents |
| 03/24/2005 | US20050065111 Concurrent administering cancer drug and glucan; synergistic mixture |
| 03/24/2005 | US20050065110 Synergistic mixture; antioxidant; cardiovascular disorders; antidiabetic agents |
| 03/24/2005 | US20050065109 Crohn's disease; inflamamtory bowel disorders; sepsis; pancreatitis |
| 03/24/2005 | US20050065108 Antidiabetic agents; antilipemic agents |
| 03/24/2005 | US20050065107 Plasmids suitable for IL-2 expression |
| 03/24/2005 | US20050065102 Medicinal compositions |
| 03/24/2005 | US20050065101 Halogenation with a diphenylhalosulfonimide, deblocking the protected hydroxyl group; optional esterification or addition salt formation |
| 03/24/2005 | US20050065100 Concurrent administering regimen for controlling hypothalamus, pituary and adrenal glands with antiacne drug |
| 03/24/2005 | US20050065099 Treatment of mitochondrial diseases |
| 03/24/2005 | US20050065098 Antidiabetic agents; hypoglycemic agents; dietetics; bioavailability |
| 03/24/2005 | US20050065097 Liver disorders; antiarrhythmia agents; anticancer agents; astaxanthin |
| 03/24/2005 | US20050065096 Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease |
| 03/24/2005 | US20050065095 Antibacterial agents |
| 03/24/2005 | US20050065094 Synergistic mixture with other drug; side effect reduction |
| 03/24/2005 | US20050065093 Inhibitors of the ICE/ced-3 family of cysteine proteases |
| 03/24/2005 | US20050065091 Containing antioxidant, free radical scavenger ; topical solution containing vitamin c, vitamin e |
| 03/24/2005 | US20050065088 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and parathyroid hormone |
| 03/24/2005 | US20050065087 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bone morphogenetic protein |
| 03/24/2005 | US20050065084 polynucleotide codes for saratin polypeptides from saliva of leeches, used as antagonist for collagen-dependent platelet adhesion; genetic engineering; prophylaxis of cardiovascular disorders |
| 03/24/2005 | US20050065080 Use of leptin in fertility |
| 03/24/2005 | US20050065067 tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin; free of leukocytes (white blood cells) and platelets |
| 03/24/2005 | US20050065066 Stabilised insulin compositions |
| 03/24/2005 | US20050065065 Modulation of the expression of estrogen receptors for the prevention or treatment of heart disease |
| 03/24/2005 | US20050065030 Reduction inhibitory agent for active oxygen eliminating activity |
| 03/24/2005 | US20050064572 Lipid kinase |
| 03/24/2005 | US20050064548 Yeast ectopically expressing abnormally processed proteins and uses therefor |
| 03/24/2005 | US20050064530 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 03/24/2005 | US20050064522 EG-VEGF nucleic acids and polypeptides and methods of use |
| 03/24/2005 | US20050064519 Using glutathione s-transferase diarylsulfonylurea binding protein (DBP) fusion as tool in detection/monitoring suppression of release of inflammatory mediators and treatment of rheumatoid arthritis, asthma, inflammation, neurodegeneration, atherosclerosis and psoriasis |
| 03/24/2005 | US20050064501 Medicaments comprising inhibitors of the cell volume-regulated human kinase h-sgk |
| 03/24/2005 | US20050064491 Transport protein for use as tool in identifying modulator for treatment of sleep, nervous suystem, anixety, eating, cardiovascular and pain disordere |
| 03/24/2005 | US20050064475 Using type II membrane glycoprotein (4F2hc) as tool in identifying modulator which inhibit transcription in tumor cells; gene expresion inhibition and antitumors agents |
| 03/24/2005 | US20050064462 Methods, compositions, and kits for predicting the effect of compounds on hot flash symptoms |
| 03/24/2005 | US20050064458 Nucleotide sequences coding membrane protein for use in diagnosis, prevention and treatnment of cell proliferative, nervous system, metabolic and inflammatory disorders |
| 03/24/2005 | US20050064440 Using single nucleotide polymorphism in contactin-2 (CNTN-2) and kinesin-7 (CENP-E) genes as diagnostic indicators of cell proliferative disorders; antitumor agents; ribozymes and tumor treatment; RNA interference |
| 03/24/2005 | US20050064437 Oligonucleotides and methods for detecting hepatitis B viral nucleic acids |
| 03/24/2005 | US20050064407 Bcl-2 dnazymes |
| 03/24/2005 | US20050064404 Regulation of human serotonin-like g protein-coupled receptor |
| 03/24/2005 | US20050064388 Methods and compositions for treating atheroma, tumors and other neoplastic tissue |
| 03/24/2005 | US20050064382 exposing cells to a complex of 2,4-dihydroxy-6-methylpyrimidine with N-methyl-D-glucamine, for treatment of medical conditions characterized by excessive or inappropriate apoptosis such as ischemia, diabetes, strokes, Alzheimer's, and Parkinson's diseases; cryoprotectants |
| 03/24/2005 | US20050064070 Beverage compositions for use in rehydration and nutrition during athletic exercise and methods of making same |
| 03/24/2005 | US20050064051 Oral Rinse |
| 03/24/2005 | US20050064050 Administering an effective amount of thearubigin, a type of brown-colored pigment component of black tea extracted from the leaves by water, hot water or an alcohol; an oxidative derivative of theaflavin (1-oxo,2,8,9-tri(hydroxy),4,6-bis(3,5,7-trihydroxy)chroman-2-yl)-benzocycloheptene; drugs; foods |
| 03/24/2005 | US20050064047 Topical mixture of sulfur, selenium sulfide, and a carrier vehicle where a weight percent of sulfur is equal to or greater than that of the carrier vehicle; curing skin irritations, dermatitis, tinea versicolor or sun spots, seborrheic keratoses, foot fungus, e.g., athelete's foot, and tinea cruris |
| 03/24/2005 | US20050064045 Chemical ablation agent to cause tissue necrosis, and a biodegradable viscosity agent to form a highly viscous formulation for injection; prostatic ablation to treat benign prostatic hyperplasia |
| 03/24/2005 | US20050064044 Administering Glycogen synthase kinase 3 (GSK-3) inhibitors such as lithium chloride to treat osteoporosis for example; drug screening |
| 03/24/2005 | US20050064043 Ingesting a combination of dosage form of liquid, ingested in a series of sequential dosage: a first dose of bisacodyl;) a 2nd dose in a combination of bisacodyl, metoclopramide, a phosphorus compound and sodium, 3rd dose of phosphorus compounds and sodium, 4th dose of metoclopramide |
| 03/24/2005 | US20050064037 Transdermal delivery of oxybutynin in gel formulations |
| 03/24/2005 | US20050064035 Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
| 03/24/2005 | US20050064032 Dosage form, device, and methods of treatment |
| 03/24/2005 | US20050064031 Combination contraceptive, kits that contain the latter, and a method that uses the latter |
| 03/24/2005 | US20050064030 Making a tablet by combining a drug with an effervescent agent used as penetration enhancer to influence the permeability of the medicament in the oral cavity; compressing to form tablet |
| 03/24/2005 | US20050064029 Stable pharmaceutical composition |
| 03/24/2005 | US20050064028 Pharmaceutical compositions containing plasma protein |
| 03/24/2005 | US20050064027 Prolonged gastric retention time due to bioadhesion (which may be polymers, metal oxides, or ligands for specific mucosal components); macrospheres for delivery of acyclovir for example |
| 03/24/2005 | US20050064025 With a phospholipid such as dipalmitoyl phosphatidylcholine, and an antiinflammatory drug such as a nonsteroidal, anti-inflammatory drug (NSAID) such as celecoxib |
| 03/24/2005 | US20050064022 Contains amorphous terazosin; treating benign prostatic hypertrophy; maximizes the dosage interval and minimizes the plasma concentrations and or fluctuations in plasma concentrations |
| 03/24/2005 | US20050064018 Use of vitamin D compounds |
| 03/24/2005 | US20050064017 feeding dog or cat the pet food including 5-40% by weight protein, 5-45% by weight fat, 0.1 to 12% by weight fiber, 1 to 90% by weight digestible carbohydrate, 0.1-2% by weight functional ingredient to build lean muscle mass |
| 03/24/2005 | US20050064014 Use of cystathionine |
| 03/24/2005 | US20050064013 liquid beverage product for consumption by humans for restoring human growth hormone containing (A) pantothenic acid; (B) boron; (C) chromium; (D) copper; (E) isoleucine; (F) leucine;(G) valine; (H) choline; (I) arginine; and (J) water; dietary supplement for athletes and bodybuilders |
| 03/24/2005 | US20050064012 instilling a bio-compatible material containing bio-compatible molecules to the cornea of the eye, cornea has a first composite refractive index, such bio-compatible molecules alter first composite refractive index to a second composite refractive index |
| 03/24/2005 | US20050064010 Transscleral delivery |
| 03/24/2005 | US20050064006 Stents |
| 03/24/2005 | US20050063998 completely dissolving galantamine or salt , intense sweetener, in a bulk liquid carrier to form a solution, diluting the solution with purified wate; Alzheimer disease and related dementia, mild cognitive impairment (MCI), Lewy body disease (LBD), Parkinson disease, schizophrenia |
| 03/24/2005 | US20050063997 Mixture of macrolactone antibodies and mycophenolic acid ; antiinflammatory agents; antiproliferative agents; topical drug |
| 03/24/2005 | US20050063996 Ocular solutions |
| 03/24/2005 | US20050063992 administering to a patient 2-methylene-19-nor-20(S)-1 alpha ,25-dihydroxyvitamin D3 and an estrogen, or a salt or prodrug for treating senile osteoporosis, postmenopausal osteoporosis, bone fracture, bone graft, breast cancer, prostate cancer, obesity, osteopenia, muscle damage or sarcopenia |
| 03/24/2005 | US20050063991 administrating. to a diabetic or arteriosclerosis patient an effective amount of crude Dunaliella powder containing an approximately 1:1 ratio of all-trans and 9-cis beta -carotene |
| 03/24/2005 | US20050063990 Compositons and methods for weight loss |
| 03/24/2005 | US20050063980 An alginate, a pectin and an antacid, such as sodium or potassium bicarbonate; gastrointestinal reflux disease |
| 03/24/2005 | US20050063971 Monoclonal or humanized antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, polypeptide fragment, polynucleotide or antibody |
| 03/24/2005 | US20050063965 Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes |
| 03/24/2005 | US20050063958 Ex vivo gene therapy for HIV; formulation of CD34+ hematopoietic cells transduced with a viral construct which expresses an anti-HIV agent such as a ribozyme |
| 03/24/2005 | US20050063940 Use of (poly)ethoxylated fatty acid glycerides for enhancing bioadhesion of a liquid pharmaceutical applied to a mucous membrane; use delivering active agents to plants, fish gills |
| 03/24/2005 | US20050063939 Novel biodegradable elastomeric scaffold for tissue engineering and light scattering fingerprinting methods for testing the same |
| 03/24/2005 | US20050063938 Tertiary amine functional complex polyester polymers and methods of production and use |
| 03/24/2005 | US20050063937 Multiple-arm peptide compounds, methods of manufacture and use in therapy |
| 03/24/2005 | US20050063913 Novel metaxalone compositions |
| 03/24/2005 | US20050063912 Process for manufacturing bulk solutions and a lyophilized pure alpha-aztreonam lysinate |
| 03/24/2005 | US20050063909 Drug and adverse-effect agent coated with inner acid-soluble layer and outer base-soluble layer; sustained release; multilayer tablets; for treatment of pain with opiod analgesics |
| 03/24/2005 | US20050063905 Administering a RADIONUCLIDE COMPLEXED WITH A CHELATING AGENT SUCH AS MACROCYCLIC AMINOPHOSPHONIC ACID, or tetraazacyclododecanetetramethylenephosphonic acid (DOTMP); polycythemia vera, macroglobulinemia (Waldenstrom syndrome), megakaryocytic myelosis, malignant histiocytosis |
| 03/24/2005 | US20050063903 Combined use of cruciferous indoles and chelators for the treatment of papilloma virus-related conditions |
| 03/24/2005 | US20050061314 Metered dose inhaler |
| 03/24/2005 | DE10341264A1 Schmelzformulierte, multipartikuläre orale Darreichungsform Melting formulated, multiparticulate oral dosage form |
| 03/24/2005 | DE10341233A1 Composition, useful to treat e.g. atrial fibrillation, atrial flutter and atrial arrhythmia, comprises at least one beta-blocker and at least one compound of a phenylcarboxylic acid amide derivative |
| 03/24/2005 | DE10340428A1 Opioides Analgetikum enthaltende transdermale Formulierung Opioid analgesic containing transdermal formulation |
| 03/24/2005 | DE10340417A1 Water-in-oil emulsion for treating neurodermatitis, dyskeratosis, scars, aged skin, liver spots, pruritis, vitiligo and scleroderma and for tautening connective tissues comprises phytosterols |
| 03/24/2005 | DE10340068A1 New inhibitors of non-ribosomal peptide synthetase adenylation domains useful in therapeutic compositions comprise aminoacyl sulfamoyl adenosine derivatives |